Kynexis

Kynexis is a clinical-stage biotech headquartered in Naarden, Netherlands, developing precision therapeutics for brain diseases. Its lead program, KYN-5356, is a KAT-II inhibitor in Phase 2 trials for cognitive impairment associated with schizophrenia, backed by investors including Forbion and Novartis.

  • Series A
  • Biotechnology
  • Clinical Trials
  • Mental Health
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Aug 19, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Aug 19, 2026

    EUR 97M

    Series A

    Led by Novartis Venture Fund

    • Forbion
    • Sunstone Life Science Ventures
    • Novartis Venture Fund
    • Ysios Capital

    Article coming soon.

Pricing

Research Kynexis — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Get started

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Get started

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Kynexis is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

Start freeAll fundingVisit website
© 2026 VeilStrat. All rights reserved.All systems operational